

monitor

MOLECULES

A novel antifungal anthraquinone from *Saproisma fragrans*


The clinical relevance of fungal diseases has increased enormously as a result of the growing number of immunocompromised subjects (e.g. individuals infected with HIV, transplant recipients and patients with cancer) [1,2]. By contrast, adequate treatment of mycotic infections is difficult because the long-term use of several common antifungals can have toxic effects. In addition, many compounds have a limited spectrum and efficacy, and their use can result in strain resistance [3].

As part of their ongoing studies in this field, Singh and collaborators [4] recently reported their results on the isolation and characterization of a new anthraquinone (**i**) and the known compound **ii** [5] from the ethanolic extract of the aerial part of *Saproisma fragrans*. The structure of **i** as the 3,4-dihydroxy-1-methoxyanthraquinone-2-carboxaldehyde was attributed on the basis of IR, NMR and mass analyses. Compound **i** generated minimum inhibitory concentration (MIC) values of 12.5 µg/ml against *Trichophyton mentagrophytes* and 25 µg/ml against *Sporothrix schenckii*, whereas the MIC values for compound **ii** were 1.56 µg/ml and 6.25 µg/ml against *Trichophyton mentagrophytes* and *Sporothrix schenckii*, respectively. In the same tests, the MIC values for clotrimazole, chosen as a standard antifungal, were 0.39 µg/ml and

1.56 µg/ml against *Trichophyton mentagrophytes* and *Sporothrix schenckii*, respectively. On these bases, further chemical studies on compounds **i** and **ii** could lead to a new potent antifungal drug.

and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. *Antimicrob. Agents Chemother.* 43, 702–704

4 Singh, D.N. et al. (2006) Antifungal anthraquinones from *Saproisma fragrans*. *Bioorg. Med. Chem. Lett.* 16, 4512–4514



(i) $R_1 = \text{CHO}$; $R_2 = \text{OH}$

(ii) $R_1 = \text{CHO}$; $R_2 = \text{H}$

1 Clark, T.A. et al. (2002) Recent trends in the epidemiology of invasive mycoses. *Curr. Opin. Infect. Dis.* 15, 569–574

2 Hage, C.A. et al. (2002) Mucosal and invasive fungal infections in HIV/AIDS. *Eur. J. Med. Res.* 7, 236–241

3 Helmerhorst, E.J. et al. (1999) Amphotericin B- and fluconazole-resistant *Candida* spp., *Aspergillus fumigatus*,

5 Murti, V.V.S. et al. (1972) Chemical components of *Rubia iberica*. *Indian J. Chem.* 10, 246–247

Daniela Barlocco

daniela.barlocco@unimi.it